Frans Van de Werf

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

Jennifer B. Green, M. Angelyn Bethel, Paul W. Armstrong et al. · New England Journal of Medicine · 2015 · 2.6K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus

Darren K. McGuire, Frans Van de Werf, Paul W. Armstrong et al. · JAMA Cardiology · 2016 · 218 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: The ASSENT-1 trial

Frans Van de Werf, Christopher P. Cannon, Anne Luyten et al. · American Heart Journal · 1999 · 158 citations

Medicine, Cardiology, Internal Medicine +13

Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype

Eberhard Standl, Susanna R. Stevens, Paul W. Armstrong et al. · Diabetes Care · 2018 · 75 citations

Medicine, Cardiology, Geriatric Medicine +16

Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS

Joakim Alfredsson, Jennifer B. Green, Susanna R. Stevens et al. · Diabetes Obesity and Metabolism · 2018 · 73 citations

Medicine, Cardiology, Endocrinology +17